For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$39.10
Thesis
CRISPR Therapeutics commercialized one of the first approved CRISPR-based medicines and is extending editing into in vivo and immuno-oncology programs. An approved therapy plus a deep pipeline anchors a leading position in gene editing.
Catalysts
- Casgevy commercial ramp and patient starts
- In vivo editing program readouts
- Cell-therapy and cardiovascular pipeline progress
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 12Trial initiationClinicalTrials.gov
CRISPR Therapeutics begins recruiting for Phase 1/2 trial of CTX340 in hypertension (NCT07758634).
- Nov 5Trial readoutClinicalTrials.gov
CRISPR Therapeutics completes Phase 1 trial NCT05795595 of CTX131 in relapsed/refractory solid tumors
- Nov 2Financial resultsSEC
CRISPR Therapeutics AG filed 8-K (items 2.02, 9.01) disclosing financial results.
- Oct 20Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease; status recruiting.
- Oct 19LeadershipSEC
8-K reports item 5.02 leadership change (director/officer departure or appointment).
- Sep 24Trial initiationClinicalTrials.gov
Long-term follow-up study (NCT06208878) of CRISPR CAR T therapies updated to ENROLLING_BY_INVITATION status.
- Sep 22Trial initiationClinicalTrials.gov
CRISPR Therapeutics initiates Phase 1/2 trial (NCT07549698) of CTX112 in relapsed/refractory hematologic autoimmune disease.
- Sep 18Trial initiationClinicalTrials.gov
CRISPR Therapeutics Phase 1 trial NCT07491172 for CTX310 in refractory dyslipidemias begins recruiting.